<DOC>
	<DOCNO>NCT02435849</DOCNO>
	<brief_summary>This single arm , open-label , multi-center , phase II study determine efficacy safety CTL019 pediatric patient r/r B-cell ALL .</brief_summary>
	<brief_title>Determine Efficacy Safety CTL019 Pediatric Patients With Relapsed Refractory B-cell ALL</brief_title>
	<detailed_description>This single arm , open-label , multi-center , phase II study determine efficacy safety CTL019 pediatric patient r/r B-cell ALL . The study follow sequential phase : Screening , Pre-Treatment ( Cell Product Preparation &amp; Lymphodepleting Chemotherapy ) , Treatment Primary Follow-up , Secondary Follow-up ( applicable ) Survival Follow-up . The total duration study 5 year CTL019 cell infusion .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Relapsed refractory pediatric Bcell ALL . 1 . 2nd great Bone Marrow ( BM ) relapse OR . 2 . Any BM relapse allogeneic stem cell transplantation ( SCT ) must ≥ 6 month SCT time CTL019 infusion OR . 3 . Primary refractory define achieve CR 2 cycle standard chemotherapy regimen chemorefractory define achieve CR 1 cycle standard chemotherapy relapse leukemia OR . 4 . Patients Philadelphia chromosome positive ( Ph+ ) ALL eligible intolerant fail 2 line tyrosine kinase inhibitor therapy ( TKI ) , TKI therapy contraindicate OR . 5 . Ineligible allogeneic SCT . For relapsed patient , documentation CD19 tumor expression demonstrate bone marrow peripheral blood flow cytometry within 3 month study entry . Adequate organ function define : 1 . Renal function define : A serum creatinine base age/gender follow : Maximum Serum Creatinine ( mg/dL ) . Age Male Female 1. &lt; 2 year 0.6 0.6 2. &lt; 6 year 0.8 0.8 6 &lt; 10 year 1.0 1.0 10 &lt; 13 year 1.2 1.2 13 &lt; 16 year 1.5 1.4 ≥ 16 year 1.7 1.4 . 2 . Alanine Aminotransferase ( ALT ) ≤ 5 time upper limit normal ( ULN ) age . 3 . Bilirubin &lt; 2.0 mg/dL . 4 . Must minimum level pulmonary reserve ≤ Grade 1 dyspnea pulse oxygenation &gt; 91 % room air . 5 . Left Ventricular Shortening Fraction ( LVSF ) ≥ 28 % confirm echocardiogram ( ECHO ) , Left Ventricular Ejection Fraction ( LVEF ) ≥ 45 % confirm echocardiogram Multiple Uptake Gated Acquisition ( MUGA ) . Bone marrow ≥ 5 % lymphoblast morphologic assessment screening . Life expectancy &gt; 12 week . Age 3 time screen age 21 time initial diagnosis Karnofsky ( age ≥ 16 year ) Lansky ( age &lt; 16 year ) performance status ≥ 50 screening . Must apheresis product nonmobilized cell receive accepted manufacturing site . Isolated extramedullary disease relapse Patients concomitant genetic syndrome : patient Fanconi anemia , Kostmann syndrome , Shwachman syndrome know bone marrow failure syndrome . Patients Down Syndrome exclude . Patients Burkitt 's lymphoma/leukemia ( i.e . patient mature Bcell ALL , leukemia Bcell [ sIg positive kappa lambda restrict positivity ] ALL , FAB L3 morphology /or MYC translocation ) Prior malignancy , except carcinoma situ skin cervix treat curative intent evidence active disease Treatment prior gene therapy product Has treatment prior antiCD19/antiCD3 therapy , antiCD19 therapy Active latent hepatitis B active hepatitis C ( test within 8 week screen ) , uncontrolled infection screen Human Immunodeficiency Virus ( HIV ) positive test within 8 week screen Presence grade 2 4 acute extensive chronic graftversushost disease ( GVHD ) . Active CNS involvement malignancy , define CNS3 per NCCN guideline . Patient investigational medicinal product within last 30 day prior screen . Pregnant nursing woman . Women childbearing potential ( defined woman physiologically capable become pregnant ) male participant , unless use highly effective method contraception period 1 year CTL019 infusion . Highly effective contraception method include : 1 . Total abstinence ( line prefer usual lifestyle patient . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal NOT acceptable method contraception 2 . Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment 3 . Male sterilization ( least 6 month prior screen ) . For female patient study vasectomized male partner sole partner patient . 4 . BOTH follow form contraception must utilize : Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception . Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository 5 . Use IUDs exclude due increase risk infection bleed population . 6 . In case use oral contraception , woman must stable pill minimum 3 month take study treatment . Women reproductive potential ( define either &lt; 11 year age , Tanner Stage 1 , postmenopausal least 24 consecutive month undergone hysterectomy , salpingotomy , and/or bilateral oophorectomy ) eligible without require use contraception . Acceptable documentation include write oral documentation communicate clinician clinician 's staff one following : 1 . Demographics show age &lt; 11 2 . Physical examination indicate Tanner Stage 1 3 . Physician report/letter 4 . Operative report source documentation patient record 5 . Discharge summary 6 . Follicle stimulate hormone measurement elevate menopausal range The following medication exclude : 1 . Steroids : Therapeutic dos steroid must stop &gt; 72 hour prior CTL019 infusion . However , follow physiological replacement dos steroid allow : &lt; 12 mg/m2/day hydrocortisone equivalent 2 . Allogeneic cellular therapy : Any donor lymphocyte infusion ( DLI ) must complete &gt; 6 week prior CTL019 infusion 3 . GVHD therapy : Any drug use GVHD must stop &gt; 4 week prior CTL019 infusion ( e.g . calcineurin inhibitor , methotrexate chemotherapy drug , mycophenolyate , rapamycin , thalidomide , immunosuppressive antibody antiCD20 ( rituximab ) , antiTNF , antiIL6 antiIL6R ) 4 . Chemotherapy : The follow drug must stop &gt; 1 week prior CTL019 infusion administer concomitantly follow lymphodepleting chemotherapy : hydroxyurea , vincristine , 6mercaptopurine , 6thioguanine , methotrexate &lt; 25 mg/m2 , cytosine arabinoside &lt; 100 mg/m2/day , asparaginase ( nonpegylated ) The following drug must stop &gt; 2 week prior CTL019 infusion : salvage chemotherapy ( e.g . clofarabine , cytosine arabinoside &gt; 100 mg/m2 , anthracyclines , cyclophosphamide ) , exclude require lymphodepleting chemotherapy drug Pegylatedasparaginase must stop &gt; 4 week prior CTL019 infusion 5 . CNS disease prophylaxis : CNS prophylaxis treatment must stop &gt; 1 week prior CTL019 infusion ( e.g . intrathecal methotrexate ) Anti Tcell therapy : Administration T cell toxic agent strongly discourage since residual lytic level may destroy infused CTL019 cell prevent vivo expansion . Other protocoldefined inclusion/exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pediatric , ALL , Cell therapy</keyword>
</DOC>